...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of women’s health >Changes in hemostatic parameters after oral hormone therapy in postmenopausal women.
【24h】

Changes in hemostatic parameters after oral hormone therapy in postmenopausal women.

机译：绝经后妇女口服激素治疗后止血参数的变化。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Oral hormone therapy (HT) and menopausal age are both prothrombotic risk factors. The aim of our study was to compare the hemostatic parameters in plasma of postmenopausal women after 6 months of oral HT with parameters of control (without treatment) postmenopausal women. METHODS: Twenty-seven postmenopausal women were treated with 17beta-estradiol (1 mg) and dydrogesterone (5 mg) daily for 6 months. The control group (27 women) did not receive any HT. Hemostatic factors, such as fibrinogen (FG) concentration, activated partial thromboplastin time (APTT), platelet (PLT) count, maximum velocity of clot formation, and fibrin lysis half-time were estimated. RESULTS: The hemostatic parameters in both groups differ significantly. After 6 months oral HT, APTT and the level of FG were higher than in the control group (APTT 30.08 seconds vs. 28.18 seconds, p = 0.02; FG 4.14 g/L vs. 3.03 g/L, p < 0.001). However, the higher values of maximal velocity of FG polymerization (153.53 mOD/min vs. 92.87 mOD/min, p < 0.001), maximum absorbance values (0.306 vs. 0.275, p < 0.001), and fibrin lysis half-time (32.33 minutes vs. 18.11 minutes, p < 0.001) compared with values in the control group also were observed. There was no statistically significant difference in PLT counts between control and women treated with oral HT. CONCLUSIONS: Six months of oral combined HT (17beta-estradiol and dydrogesterone) caused increased initial velocity of clot formation and inhibition of fibrinolysis. The increased level of FG and its higher polymerization may help explain the increase in venous thrombosis and cardiovascular events reported after the use of oral HT.
机译：目的：口服激素治疗（HT）和更年期都是血栓形成前的危险因素。我们研究的目的是比较绝经后妇女口服HT 6个月后血浆中的止血参数与绝经后妇女的对照（未经治疗）参数。方法：27名绝经后妇女每天接受17β-雌二醇（1毫克）和dydrogesterone（5毫克）治疗6个月。对照组（27名妇女）未接受任何HT。估计了止血因素，例如纤维蛋白原（FG）浓度，活化的部分凝血活酶时间（APTT），血小板（PLT）计数，最大血凝块形成速度和纤维蛋白裂解时间。结果：两组的止血参数明显不同。口服HT 6个月后，APTT和FG水平高于对照组（APTT 30.08秒vs. 28.18秒，p = 0.02; FG 4.14 g / L vs. 3.03 g / L，p <0.001）。但是，FG聚合的最大速度（153.53 mOD / min对92.87 mOD / min，p <0.001），最大吸光度值（0.306对0.275，p <0.001）和纤维蛋白半衰期的较高值较高（32.33）分钟与18.11分钟的比较（p <0.001），与对照组相比也是如此。对照组和口服HT治疗的女性之间的PLT计数无统计学差异。结论：口服联合HT（17β-雌二醇和dydrogesterone）治疗六个月可导致血凝块形成的初始速度增加，并抑制纤维蛋白溶解。 FG水平的升高和其更高的聚合度可能有助于解释口服HT后静脉血栓形成和心血管事件的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号